<SEC-DOCUMENT>0000950123-15-010226.txt : 20160616
<SEC-HEADER>0000950123-15-010226.hdr.sgml : 20160616
<ACCEPTANCE-DATETIME>20151013172330
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0000950123-15-010226
CONFORMED SUBMISSION TYPE:	DRSLTR
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20151013

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Merus B.V.
		CENTRAL INDEX KEY:			0001651311
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			P7
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DRSLTR

	BUSINESS ADDRESS:	
		STREET 1:		PADUALAAN 8
		STREET 2:		POSTVAK 133
		CITY:			UTRECHT
		STATE:			P7
		ZIP:			3584 CH
		BUSINESS PHONE:		31 030 253 8800

	MAIL ADDRESS:	
		STREET 1:		PADUALAAN 8
		STREET 2:		POSTVAK 133
		CITY:			UTRECHT
		STATE:			P7
		ZIP:			3584 CH

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Merus B.V.
		DATE OF NAME CHANGE:	20150819
</SEC-HEADER>
<DOCUMENT>
<TYPE>DRSLTR
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML><HEAD>
<TITLE>DRS/A LETTER (RESPONSE LETTER)</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="62%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="25%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ROWSPAN="6">


<IMG SRC="g29248corresp_logoa.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">John Hancock Tower, 27th Floor</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">200 Clarendon Street</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Boston, Massachusetts 02116</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Tel: +1.617.948.6000 Fax: +1.617.948.6001</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">www.lw.com</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">FIRM / AFFILIATE OFFICES</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ROWSPAN="16"> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">October 13, 2015</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>VIA EDGAR AND HAND DELIVERY</U></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ms.&nbsp;Suzanne Hayes</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Assistant Director</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">U.S. Securities and Exchange Commission</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Division of Corporation Finance</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">100 F Street, N.E.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mail Stop 4720</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Washington, D.C. 20549</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Abu Dhabi</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Milan</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Barcelona</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Moscow</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Beijing</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Munich</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Boston</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">New Jersey</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Brussels</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">New York</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Century&nbsp;City</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Orange County</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chicago</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Paris</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Dubai</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Riyadh</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">D&uuml;sseldorf</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Rome</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Frankfurt</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">San Diego</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Hamburg</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">San Francisco</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Hong Kong</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Shanghai</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Houston</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Silicon Valley</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">London</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Singapore</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Los Angeles</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Tokyo</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Madrid</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Washington, D.C.</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">Re:</TD>
<TD ALIGN="left" VALIGN="top"><U>Merus B.V. Registration Statement on Form F-1 (CIK No.&nbsp;0001651308) </U> </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Ms.&nbsp;Hayes: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On behalf of Merus B.V. (the &#147;<B><I>Company</I></B>&#148;), we are transmitting this letter in response to comments received from the
staff (the &#147;<B><I>Staff</I></B>&#148;) of the Securities and Exchange Commission (the &#147;<B><I>Commission</I></B>&#148;) by letter dated October&nbsp;5, 2015 with respect to the Company&#146;s draft Registration Statement on Form F-1 (the
&#147;<B><I>Initial Confidential Registration Statement</I></B>&#148;). This letter is being submitted together with an amendment to the Initial Confidential Registration Statement (as amended, the &#147;<B><I>Registration Statement</I></B>&#148;),
which has been revised to address various of the Staff&#146;s comments. The bold and numbered paragraphs below correspond to the numbered paragraphs in the Staff&#146;s letter and are followed by the Company&#146;s responses. For the Staff&#146;s
convenience, we are also sending, by courier, copies of this letter and marked copies of the Registration Statement that reflect changes made to the Initial Confidential Registration Statement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Summary </U></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Please describe how binding to two different antigens produces products that have greater potency and lower toxicity than existing cancer therapeutics. </B></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><U>Response</U>: In response to the Staff&#146;s comment, the Company has revised the disclosure on pages 1, 65 and 81 of the Registration
Statement. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>October 13, 2015 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B> Page
 2
 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g29248corresp_logob.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Our Product Pipeline, page 2 </U></B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Please remove the last row from this table and the corresponding one on page 82, as the research described therein is in too preliminary a stage to be reflected in a table intended to represent your product pipeline.
</B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><U>Response</U>: In response to the Staff&#146;s comment, the Company has revised the disclosure on pages 2 and 83 of
the Registration Statement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Our Biclonics platform, page 2 </U></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Please briefly explain what the &#147;Fc&#148; region of your Biclonics is and define &#147;transgenic&#148; mice. </B></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><U>Response</U>: In response to the Staff&#146;s comment, the Company has revised the disclosure on pages 3, 4 and 85 of the Registration
Statement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Benefits of Biclonics, page 4 </U></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Please briefly explain what &#147;heterodimer formation&#148; is. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><U>Response</U>: In
response to the Staff&#146;s comment, the Company has revised the disclosure on pages 4 and 88 of the Registration Statement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Risks Associated with
Our Business, page 6 </U></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Please include a bullet point that addresses the risk presented by the need to defend against patent infringement claims, as reflected in your risk factor on pages 40-41, and reference the pending lawsuit filed
against you by Regeneron Pharmaceuticals Inc. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><U>Response</U>: In response to the Staff&#146;s comment, the Company has
revised the disclosure on page 6 of the Registration Statement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Use of Proceeds, page 58 </U></B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Please amend this disclosure to indicate the approximate amount of offering proceeds you intend to allocate toward each of your bispecific antibody candidates and working capital and other general corporate purposes.
Please also indicate how far in the development process you expect that the funds from the offering will allow you to proceed with respect to each of your product candidates. For example, you should indicate whether the proceeds allocated to the
development of MCLA-128 will allow you to complete Phase 1/2 clinical studies for that product candidate. </B></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><U>Response</U>: In response to the Staff&#146;s comment, the Company has revised the disclosure on page 58 of the Registration Statement. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>October 13, 2015 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B> Page
 3
 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g29248corresp_logob.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Capitalization, page 60 </U></B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>You include the automatic conversion of your preferred stock in your pro forma presentations. Please demonstrate to us how the automatic conversion is directly attributable to your IPO and factually supportable as
required by Item&nbsp;11-02(b)(6) of Regulation S-X. In this regard, please demonstrate to us that your IPO will result in gross proceeds of at least &#128;30.0&nbsp;million at a price per share of at least four times the original issue price of
your Class B preferred shares as disclosed on page F-21. In your response, please tell us the conversion rate of each series of preferred stock and revise your disclosure in Note 15 accordingly, consistent with the guidance in paragraph 79(a)(v) of
IAS 1. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><U>Response</U>: In response to the Staff&#146;s comment, the Company has provided additional disclosure on pages
F-47 and F-48 of the Registration Statement. The Company supplementally advises the Staff that in August 2015, in connection with the closing of the Class C Financing, the terms of a qualified public offering requiring conversion of all shares of
the Company&#146;s convertible preferred shares into common shares were changed to be not less than $50.0 million and a price per share to the public of not less than one and a half times the original issue price of the Class C preferred shares. The
Company further advises the Staff that the Company expects to receive the requisite consent from the preferred shareholders to effect the conversion of all outstanding preferred shares into common shares prior to the closing of the offering.
Consequently, the Company advises the Staff that it expects that there will not be any threshold requirements that must be satisfied in order for all of the outstanding preferred shares to be converted into common shares. The conversion rate of each
class of preferred share is one-to-one, subject to adjustment for stock splits, stock dividends, stock combinations and the like. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Management&#146;s
Discussion and Analysis of Financial Condition and Results of Operations Critical Accounting Policies and Significant Judgments and Estimates Share-Based Compensation, page 75 </U></B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>We may have additional comments on your accounting for equity issuances including stock compensation. Once you have an estimated offering price, please provide us an analysis explaining the reasons for the
differences between recent valuations of your common stock leading up to the IPO and the estimated offering price. </B></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><U>Response</U>: The Company acknowledges the Staff&#146;s comment and will provide the Staff with the analysis requested once the Company has
an estimated offering price. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>October 13, 2015 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B> Page
 4
 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g29248corresp_logob.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Business </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Collaboration Agreements, page 95 </U></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Please amend your disclosure with respect to your collaboration agreement with ONO Pharmaceutical to include the following: </B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>The amounts paid to date; </B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>The aggregate milestone payments that you are eligible to receive; and </B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>The duration of the agreement outside of termination provisions. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><U>Response</U>: In
response to the Staff&#146;s comment, the Company has revised the disclosure on pages 66, 97 and 98 of the Registration Statement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Related Party
Transactions, page 125 </U></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>10.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Please tell us why the issuance of 2.4&nbsp;million shares of Class B preferred stock in January 2015 at &#128;5.64&nbsp;per share resulted in only &#128;5.0&nbsp;million in proceeds instead of approximately
&#128;13.5 million. Also tell us why the price declined from &#128;7.50&nbsp;per share from your previous issuances of Class B preferred stock. </B></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><U>Response</U>: In response to the Staff&#146;s comment, the Company has revised the disclosure on page 133 of the Registration Statement. The
Company respectfully advises the Staff that the Company issued an aggregate of 886,524 Class B preferred shares resulting in aggregate cash proceeds of &#128;5.0 million. In connection with this issuance, the Company also issued an additional
1,520,700 of our Class B preferred shares pursuant to anti-dilution provisions included in the subscription agreement for the Company&#146;s Class B preferred shares. These additional shares were issued for no cash consideration. The Company further
advises the Staff that the price per share of &#128;5.64&nbsp;per share for the closing of the fifth tranche of the Class B preferred share financing was previously agreed upon among the Company and the Class B preferred shareholders in the
subscription agreement entered into on September&nbsp;30, 2013. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Independent Auditor&#146;s Report, page F-1 </U></B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>11.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Please explain to us why your balance sheet at January&nbsp;1, 2013 is not covered by this report. </B></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><U>Response</U>: In response to the Staff&#146;s comment, the auditor has amended its audit opinion to include reference to the January&nbsp;1,
2013 balance sheet. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Statement of Profit or Loss and Comprehensive Income, page F-4 </U></B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>12.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE="font-family:Times New Roman; font-size:10pt"><B>Paragraph 99 of IAS 1 requires presentation of expenses based on either their nature or their function, whichever provides information that is
reliable and more </B></P></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>October 13, 2015 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B> Page
 5
 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g29248corresp_logob.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>
relevant. Since your presentation appears to employ the mix of both methods, please revise your presentation to comply under one method. If you choose to present expenses based on their function,
please disclose additional information based on the nature of these expenses as required under paragraph 104 of IAS 1. </B></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><U>Response</U>: In response to the Staff&#146;s comment, the Company respectfully advises the Staff that it has considered paragraph 104 of
IAS 1 together with common practice under International Financial Reporting Standards (&#147;<B><I>IFRS</I></B>&#148;) in concluding that its disclosures are compliant with IAS 1.&nbsp;In particular, as a clinical-stage immuno-oncology company, the
Company does not differentiate between how its research and development expenditures are incurred or track its internal costs by project. The Company&#146;s focus is on total research and development expenditures which make up the majority of its
expenditures and are set forth in its income statement and for which significant judgment is not required in allocating expenditures. Accordingly, like other companies in the biopharmaceutical sector that report under IFRS, the Company does not
provide a detailed analysis of these expenditures in its income statement. However, the Company does disclose the information that is required by IAS 1.104 (depreciation and amortization and employee benefits expense). The Company presents its
expenses on a nature of expense basis, not by function type. All of the applicable line items in paragraph 102 of IAS 1 have been presented; however, the Company is voluntarily adding the line item &#147;Costs of outsourced work and other external
costs&#148; to its income statement based on paragraph 104 of IAS 1. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Notes to the Financial Statements </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>4. Significant accounting policies </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Research
and development, page F-10 </U></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>13.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>To the extent that you continue to present statements of profit or loss and comprehensive income on a nature of expense basis, please disclose the amount of your personnel expenses and depreciation and amortization
attributable to research and development, as required by paragraph 126 of IAS 38. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><U>Response</U>: In response to the
Staff&#146;s comment, the Company respectfully advises the Staff it has considered this comment in conjunction with the considerations noted in its response to comment 12 above, and based thereon, is of the opinion that the Company has disclosed the
aggregate amount of research and development expenditure recognized as an expense as stipulated in paragraph 126 of IAS 38. As the Company is in the clinical development stage, personnel expenses and depreciation and amortization expenses are
considered to be directly attributable to research and development activities. This is disclosed on page&nbsp;F-25 (note 18) and F-47 (note 13) of the Registration Statement, where it is stated that all employees are active in the area of research
and development. The Company will respectfully apply this disclosure enhancement, presenting the amounts of personnel expenses and depreciation and amortization directly attributable to research and development costs required in IAS 38.126, in its
financial statements going forward. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>October 13, 2015 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B> Page
 6
 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g29248corresp_logob.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>17. Costs of outsourced work and other external costs, page F-24 </U></B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>14.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Your research and development expenditures include IP and litigation costs. Please explain your basis for characterizing these expenses as research and development. Refer us to the authoritative literature used to
reach your conclusion. In your response, at a minimum please tell us how costs to maintain patents as indicated on page 67, like litigation costs, are fees to register a legal right, as stipulated in paragraph 66(c) of IAS 38. </B></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><U>Response</U>: In response to the Staff&#146;s comment, the Company respectfully advises the Staff it considers intellectual property
(&#147;<B><I>IP</I></B>&#148;) costs directly attributable costs necessary for the preparation of an intangible asset to be capable of operating in the manner intended by management in accordance with paragraph 66 of IAS 38. Paragraph 66 of IAS 38
gives examples of directly attributable costs, including &#147;fees to register a legal right.&#148; The Company regards the protection of its patents as analogous to the costs required to register a legal right and thus, considers IP costs as fees
to register a legal right. IP costs are, therefore, presented in the Company&#146;s income statement as part of research and development expenses. Since these IP costs were incurred in the Company&#146;s pre-clinical development phase, the Company
cannot demonstrate that the bispecific antibody candidate will generate probable future economic benefits, and accordingly, IP was expensed to the Company&#146;s income statement as incurred, based on paragraph 54 of IAS 38. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company respectfully advises the Staff that litigation costs incurred by the Company in 2014 to defend itself from its
patent infringement lawsuit with Regeneron Pharmaceuticals Inc. as well as to safeguard and maintain its intellectual property portfolio are considered an integral and crucial part of the Company&#146;s business activity. Without a viable bispecific
antibody candidate, the Company would have no potential marketable therapeutics. The Company expects to continue to incur significant operating losses as it continues its research and development efforts and seek to obtain regulatory approval and
commercialization of its bispecific antibody candidates. The Company&#146;s management, therefore, maintains these costs are part of the regulatory compliance framework of its research and development activities. As such, management considers the
litigation costs to be necessary to allow the asset to be capable of operating in the manner intended by management and these costs are presented as research and development costs under paragraph 66 of IAS 38. These expenses were identified and
disclosed separately as &#147;IP and litigation costs&#148; in addition to the line items &#147;Manufacturing costs&#148; and &#147;Research and development costs&#148; and were included in research and development costs under &#147;Costs of
outsourced work and other external costs&#148; in the Company&#146;s income statement for the year ended December&nbsp;31, 2014. The Company respectfully advises that both &#147;Other operating expenses&#148; and &#147;Research and development
costs&#148; are presented in the line item &#147;Costs of outsourced work and other external costs&#148; in the Company&#146;s income statement, and litigation costs are disclosed and captured in the same line item. In
</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>October 13, 2015 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B> Page
 7
 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g29248corresp_logob.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
addition to being visibly presented in research and development expenditure, the nature and description of the litigation costs are disclosed in the Company&#146;s financial statements. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the aforementioned considerations, the Company respectfully acknowledges the Staff&#146;s comment and has amended its interim
unaudited financial statements for the six months ended June&nbsp;30, 2015 and going forward to account for future litigation costs as part of &#147;Other operating expenses&#148; and not research and development expenses. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>27. Adoption of IFRS, page F-31 </U></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>15.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Please revise your disclosure to provide all of the reconciliations required by paragraph 24 of IFRS 1, particularly the reconciliation of equity. In addition, please tell us the extent to which you applied the
exceptions discussed in paragraph 13 and Appendix B of IFRS 1 and the exemptions discussed in paragraph 18 and Appendices C through E of IFRS 1. To the extent you applied any exception or exemption, please revise your disclosure to describe how you
applied them. See Instruction 4 to Item&nbsp;5 of Form 20-F. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><U>Response</U>: In response to the Staff&#146;s comment,
the Company respectfully advises the Staff that total equity under generally accepted accounting principles in the Netherlands (&#147;<B><I>Dutch GAAP</I></B>&#148;) and IFRS are equal. Share-based payments were accounted for under the
&#147;intrinsic value&#148; method under Dutch GAAP. The accounting entries are reported the same as under IFRS 2. However, instead of fair value, the intrinsic value of the share options is expensed to the Company&#146;s profit and loss account
over the vesting period (with a corresponding credit entry in equity for the same intrinsic value amount). Since the intrinsic value of the share options is lower than their fair value, a higher share-based payment expense was accounted for in
Company&#146;s profit and loss account under IFRS (with a credit entry in equity for the fair value amount). Accordingly, there is no GAAP difference for total equity because under both Dutch GAAP and IFRS the share-based payment charge in
Company&#146;s profit and loss account is also credited in equity for the intrinsic value and fair value, respectively. The Company has disclosed the impact on net result. There are no &#147;Other Comprehensive Income&#148; items. As a result, net
result equals total comprehensive income for the Company. Accordingly, the Company believes that none of the required reconciliations in IFRS 1.24 (a)&nbsp;and (b), other than for net result, are applicable to the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company did not use hindsight in estimates and confirms compliance with IFRS 1.13. The Company did not enter into any business combinations
(past and present) and therefore, IFRS 1 Appendix C is not applicable. The Company also did not elect to use any of the exemptions in IFRS 1 Appendix D. Appendix E is not applicable to the Company. Accordingly, management concluded that none of the
exemptions in IFRS 1.18 (Appendices C-E of IFRS 1) are applicable and no additional disclosures were made in this respect. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>October 13, 2015 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B> Page
 8
 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g29248corresp_logob.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Other Comments </U></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>16.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Please supplementally provide us with copies of all written communications, as defined in Rule 405 under the Securities Act, that you, or anyone authorized to do so on your behalf, present to potential investors in
reliance on Section&nbsp;5(d) of the Securities Act, whether or not they retain copies of the communications. </B></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><U>Response</U>: The Company advises the Staff that it is providing copies of the written communications, as defined in Rule 405 under the
Securities Act, that were used in meetings with potential investors in reliance on Section&nbsp;5(d) of the Securities Act on a supplemental basis. Such materials were only made available for viewing by such investors during the Company&#146;s
presentation. Pursuant to Rule 418 under the Securities Act, such copies shall not be deemed to be filed with, or a part of or included in, the Registration Statement. Additionally, pursuant to Rule 418(b) under the Securities Act, the Company
requests that the Staff return copies of such materials to the Company. Other than these materials, the Company has not provided, and it has not authorized any person to provide, any written materials in reliance on Section&nbsp;5(d) of the
Securities Act. The Company will undertake to provide the Staff with copies of any additional written communications that are presented to potential investors in the future by it or anyone authorized to do so on its behalf in reliance on
Section&nbsp;5(d) of the Securities Act, whether or not such potential investors retain copies of the communications. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>17.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Please confirm that the graphics included in your registration statement are the only graphics you will use in your prospectus. If those are not the only graphics, please provide any additional graphics prior to
their use for our review. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><U>Response</U>: In response to the Staff&#146;s comment, the Company confirms that the
graphics included in the Registration Statement are the only graphics that will be included in the prospectus. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If you have any questions
regarding the foregoing responses or the enclosed Registration Statement, please do not hesitate to contact me by telephone at (617)&nbsp;948-6060. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">/s/ Peter N. Handrinos</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Peter N. Handrinos</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">of LATHAM&nbsp;&amp; WATKINS
LLP</P></TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">cc:</TD>
<TD ALIGN="left" VALIGN="top">Ton Logtenberg, Ph.D., Merus B.V. </TD></TR></TABLE> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Nathan Ajiashvili, Latham &amp; Watkins LLP </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g29248corresp_logoa.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g29248corresp_logoa.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ % #Q P$1  (1 0,1 ?_$ (,   (" @(#
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M[:45I$:R$SB(B0TGB:2$,M*B-LD02PIRI$.$L1)0^,2&Z,\9IM\T075[A#S
M7GV35MI!1&P(% 6'732B;KO&N^)J;3;SO@1M^27VUF$W")J*V3.SMM//J@BG
M.H&BG*4 @!"P@4\LL?G"SC0NL+.N$HM2:N]/3LBBQJQTY9E36D<D$D%B*@/=
MOI[B3)19@XQEE,@E5"6067X1D%EFEC"$81AL%5_R>>;ZYFROS<6X6V-Y:10+
M&DQ/MP1+JB1ED-Q2-)2U< [7XDP<QU]&R<[A;9=#:^6*0 !<P "+,FB2SPGY
M\99@*KW)GE/N"\<-O]#D"SQ62DZYJN#Z>BR2,*#507Q,BT0HBPU)ZU?<8;;<
M))22YH$<:E0G,# S2@D\5/)NGDA&4'+6%5[4+H[([3+C5LP6,."M-NU(JCNH
M4H7 )E8.USL9%4W:&"4*P@6)AEW(,:D@$'"$@7#PP^$-@Z=N-\5#;I'.XVI3
M/7Q,^D-PD_6V;?+ <+)2:ITM4UU4;"95FE2@ME@0WA3T^OHXY8,Y) (:&\$6
M8&4 R6%&!<3YOFN1HOY^Z/6/5"=J&<M#NSM#<CWH>A"--OD%9"KS3\PL'W00
ME>A8F$X5:05M,(\/$H:'%!A%8 @'++$.6$07W53S=W'LSW"3,LX(*2*%X]RM
M4V#: ^3AAHMN(ARYFI=)3KK1,$_Q2VHRBDG/]=3$P8C*8@5Y)(:$0N,2$\09
M([+UKB'CYZ:86 4D<R:FVZ4ELO<=Q]U";%IM]54EYU.==4&C3EMR.I0(F%EL
M9:86D%3@&2& F-A#"2SPGDA'A"-?< >0VZ2S2E-NE'K"9$]1O5NHJHOIE.DD
MRW6\[S8-,J2LM2>U5ULDVW,5/)!LR#S4DK"<<*,L@)H:>2/,#EV Y/%M>:?\
MA_C@MXNA(JJ.3J54:EHJ0_3!(@'E:#7!GQ/LI_"P0X30@62X/E%'/%B<T=T4
M\<&$(QEFEFB%>NZ:K'N!K7KT["+,%;R<6\.M=OQ6JLH[>?*?9=3M,3*<S4I1
M4!:-#K*.833AA=D7)%V 0,H X,09PHQGCPQA'8+&U,TZ\JWRR"K:G=7<$QKA
M+D6.R*S/=.JNRJ5)-,FSADAKJBVR4^=BDN8F"C(0Q&$!Q)I=QJ$=T\(_&,0K
MZTV\[%TBCXA[%E5N%T*XCR\>1)=JW3NW]B(K50$=+)Q;5<ZCT_%K:]&>A $$
M)&8].&JW 8Q$&# (GCY><8QN)%E,4N%EREZ7<+2"S\M+<'6%.K3<BTZ2N)P5
M J@F,MMLYM*;_ 0U);'";;0;B0D)A=JM\]PDR/. Q1LJ7E%,_5%GEE 'O ?>
M%7B^_P 85#;F;E'*ENZKSW<=84YQ+R.VD)HD#91H5:>+40I D)MDDY(*3ED1
M' #GF#"EB+-+&>;?--&.P(JL@]P9=$5\Q=<+2+VUQOF[0:@7;W(VCVUU#"8[
M69I:G=6:5U-RYB-5:=**3(#N$HNMY;24<W,H1',2*"LG&>8&%BHS ZI/O7N$
M,>X&7K!!'2D36RD/'*7N(+M#2J#*M254$JVE-.99UA E!R3DHHAJ</!1,1*\
M4>+@A-#?L ^>1:^^]IX^3VAOB&L1J[2.TUZU H&HW"5%NCJNPTFJ2^32Y%)T
M$$AC4=INZ9XM!RN3D-,8R9D/ #Q'"&FF#G+2D1XC@VZQFDUYM&J4N-IWP79M
M^\NIPM0595:U64&B3-H',5IV90VZ E-589+###;HRLFKY13,1.A0XA2YL(.:
M,8A<40EXE<M0M1II3VL)*HR,8II5=TLUE4\=LA=5@GNATU"=9=CLQ&(A3)\I
MX,RONLT&2!B,$$' 6:$9YI9?FV#%/J["WZFE7VG0A]5$*MNI[VD9\6\BGD)U
M3)(H]1%QRMBG:>JO0LA#L=N+%07*SU-.022DI%#:P?)"%R88PW#)$"(V"IS:
M6_V'3[W2OFC47\]V>QR!ZVVTDF2..]S(K:*G#4*&6M#1+%!UHZ2#,CRA21FC
M+)&:,)?C&&P6D6W4JG3R1U-PL]^LMV(*+,/(L+39="(OI25.6+0.F)%%023Q
MLH2$ )S0%GE$GEC*'&$T?A'?L%"ZV.NEQMW-1O+[=R@^*NX*^>C7DS5GI;53
M6K;'J;3=CH#9MEI@G..DR$W6X1?$LRE.K#E@D\\<,EY0R\%5,#B']8(6;8'5
M>UIN'?+V\?CEL_K:G+#:N#\=M9GI;34-FN:4()SM]NA*J@NL<HK%PQ)X R(
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M<&IN5JS]59GK;,L?F7Y['<[G?/OV"%K6_32[Y+XNU;2'>IBF3WR:0ZE<W-N
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0_O/.W8OY]@-+8.;!S8/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g29248corresp_logob.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g29248corresp_logob.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ #P"F P$1  (1 0,1 ?_$ &4   ,!  ,!
M      <("08#! H% 0$                     $   !P$!  (!! (#
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=S8N1?O']G_\ 87Z0<+&N_<OY'\$GQ^[XD_H/_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
